In this episode, Prof Galle, a hepatologist and Professor of Medicine at University Medical Center Mainz, Germany, has an in-depth conversation with co-hosts Zee and John of MedInsights Unleashed on the late breaking data, CM9DW, presented at ASCO 2024. The episode covers:

– **Cutting-Edge Therapies:** Explore the transformation in HCC treatment from surgery and transplantation to the latest immunotherapies. Discover how IV therapies demonstrate superior efficacy and manageable toxicity compared to oral options.

– **Checkmate 9DW Trial Insights:** Get an in-depth analysis of the pivotal Checkmate 9DW trial, comparing immunotherapy agents (Nivolumab and Ipilimumab) with tyrosine kinase inhibitors (lenvatinib or sorafenib). Learn about the trial’s diverse patient population and the critical role of alpha fetoprotein as a prognostic marker.

– **Combination vs. Monotherapy:** Hear why combination therapies are setting new benchmarks in complete response rates and overall survival, offering new hope for liver cancer patients.

– **Multidisciplinary Approach:** Understand the crucial role of multidisciplinary teams in navigating complex decisions involving liver transplantation, intra-arterial therapies, and systemic treatments.

– **Patient Management and Outcomes:** Discover the significance of early side-effect management and patient education in improving long-term outcomes, reducing treatment visits, and enhancing quality of life.